USD
+$0.00
(+0.00%
)At Close (As of Oct 14, 2025)
$3.57B
Market Cap
17.59
P/E Ratio
0.85
EPS
$25.67
52 Week High
$13.50
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $220M |
Total Revenue | $426M |
Cost Of Revenue | $207M |
Costof Goods And Services Sold | $207M |
Operating Income | $139M |
Selling General And Administrative | $74M |
Research And Development | $1.8M |
Operating Expenses | $81M |
Investment Income Net | - |
Net Interest Income | -$12M |
Interest Income | $2.1M |
Interest Expense | $14M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8M |
Income Before Tax | $126M |
Income Tax Expense | -$72M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $198M |
Comprehensive Income Net Of Tax | - |
Ebit | $140M |
Ebitda | $148M |
Net Income | $198M |
Field | Value (USD) |
---|---|
Total Assets | $489M |
Total Current Assets | $331M |
Cash And Cash Equivalents At Carrying Value | $103M |
Cash And Short Term Investments | $103M |
Inventory | $170M |
Current Net Receivables | $50M |
Total Non Current Assets | $157M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $460K |
Intangible Assets Excluding Goodwill | $460K |
Goodwill | $3.5M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $8M |
Other Non Current Assets | - |
Total Liabilities | $140M |
Total Current Liabilities | $56M |
Current Accounts Payable | $20M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.2M |
Total Non Current Liabilities | $84M |
Capital Lease Obligations | $9.8M |
Long Term Debt | $72M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $82M |
Other Current Liabilities | $30M |
Other Non Current Liabilities | $1.7M |
Total Shareholder Equity | $349M |
Treasury Stock | - |
Retained Earnings | -$309M |
Common Stock | $24K |
Common Stock Shares Outstanding | $243M |
Field | Value (USD) |
---|---|
Operating Cashflow | $119M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $8M |
Capital Expenditures | $8.6M |
Change In Receivables | - |
Change In Inventory | $2.7M |
Profit Loss | - |
Cashflow From Investment | -$8.6M |
Cashflow From Financing | -$58M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | $198M |
Field | Value (USD) |
---|---|
Gross Profit | $220M |
Total Revenue | $426M |
Cost Of Revenue | $207M |
Costof Goods And Services Sold | $207M |
Operating Income | $139M |
Selling General And Administrative | $74M |
Research And Development | $1.8M |
Operating Expenses | $81M |
Investment Income Net | - |
Net Interest Income | -$12M |
Interest Income | $2.1M |
Interest Expense | $14M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8M |
Income Before Tax | $126M |
Income Tax Expense | -$72M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | $198M |
Comprehensive Income Net Of Tax | - |
Ebit | $140M |
Ebitda | $148M |
Net Income | $198M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
ADMA Biologics, Inc. is a biopharmaceutical company based in Ramsey, New Jersey, specializing in the development and commercialization of plasma-derived therapies for immunodeficiencies and infectious diseases. The company employs proprietary production technologies to produce high-quality therapeutic products, thereby enhancing patient outcomes in a significant healthcare market. With a strong pipeline and a dedication to addressing critical medical needs, ADMA is well-positioned for growth in the evolving landscape of biopharmaceuticals.